sameAs
Perception and Multisensory Integration in Neurological Patients Using fMRISafety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDPAlemtuzumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIPD)A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating PolyradiculoneuropathyExtension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)MRI in Diagnosing and Monitoring CIDPTranscriptome Analysis of the Peripheral Blood in CIDPEfficacy and Safety Study of I10E in Treatment of Patients With CIDPsCD163 & CD19 as Candidate Biomarkers in CIDP and MMNSubcutaneous Immunoglobulin Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)The Evaluation of Efficacy and Safety of Rituximab in Refractory CIDP Patients With IgG4 AutoantibodiesClinical Trial to Assess the Safety of a Novel Scaffold BiomaterialDiffusion Tensor Imaging in Chronic Inflammatory Demyelinating Polyneuropathy (PIDC)Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Chronic Inflammatory Demyelinating PolyneuropathyA First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347Phase III Efficacy, Safety, and Tolerability Study of HYQVIA/HyQvia and GAMMAGARD LIQUID/KIOVIG in CIDPEfficacy and Safety Study of I10E in the Maintenance Treatment of Patients With CIDP: Extension of PRISM Study I10E-1302Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients.Study of CIDP Patients During IVIG TreatmentImmune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)Phase III Randomized, Double-Blind, Placebo-Controlled Study of 3,4-Diaminopyridine for Demyelinating PolyneuropathyPhase III Multicenter Double Blind Controlled Trial of Human Immune Globulin Therapy in Previously Untreated Patients With Chronic Inflammatory Demyelinating NeuropathyStudy of Electrical Prognostic Factors of Response to Intravenous Immunoglobulin Treatment in Chronic Inflammatory Demyelinating PolyradiculoneuropathyDescriptive Analysis of Morphological Aspects of Nerve by Ultra-high Frequency Ultrasound (30-50MHZ) in Demyelinating Neuropathies: Inflammatory Demyelinating Polyneuropathy Chronic (IPDC), Neuropathy Multifocal Motor Block of Conducting (NMMBC)Exploratory Study of Predictive Markers of the Therapeutic Response in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Treated With Intravenous ImmunoglobulinLong-Term Tolerability and Safety of HYQVIA/HyQvia in CIDPProcessing Integration in Neurological Patients Using fMRIBiomark Study: Predict Intravenous Immunoglobulin Responders in Chronic Inflammatory Demyelinating PolyradiculoneuropathyA Study to Assess Long-term Safety, Tolerability and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating PolyradiculoneuropathyBiomarkers in PolyradiculoneuropathiesDo IgG Level Variations in CIDP and Multifocal Motor Neuropathy Patients Following Initial Intravenous Immunoglobulin Treatment Correlate With Ultimate Dosing
P1050
Q61955717-1AB7FE8C-EBF4-4236-9209-9C78EFEADB06Q63817070-4B98329C-9DDB-4860-B31D-EB20906E34F5Q63837982-F96BF80A-EC8B-4D55-BFB0-282D0C20215AQ64122309-D6FB6A2E-4543-4DCA-B854-1287BB0B77BDQ64349563-D0C20B25-5DD2-4E38-85F0-A7077D508130Q64350571-EA9EC239-DEF3-4CD9-8CC5-2B3D0FB8051DQ64393469-67572CBB-5A13-49EE-9733-A9184B0669B1Q64598635-2686C241-2C79-43C3-A440-2A5EF5DA9A3DQ64626018-9F2C24DF-228E-43C9-8908-52D8B609E954Q64659004-B9D77FD6-246C-4576-9765-4714B3C79284Q64672240-90423CA5-6A6E-41F0-A4C3-C781B38C9748Q64792003-9CD53F52-1785-4C9C-BAC1-2800DC1E80D1Q64794890-C640CAC8-79DC-4D14-B26B-8028732689C4Q64801805-2B25D377-FDF2-4D62-A635-4D202927E47DQ64806253-082CACA2-ED6F-43BE-B713-F752D1894BCCQ64819144-2D97E950-0B81-45B3-AE33-C51A16F32913Q65332960-4DBF9D18-D0D4-4EA1-8994-77D624EA96BCQ65354506-AB551660-B049-4719-9487-EEC0207E5FD6Q65373849-9A86F144-AAFD-40F2-9231-58DE4F623E04Q65474732-47C104E4-978F-45A4-9DD7-315E19B98DA5Q65543915-9C72BF00-4A45-4811-A408-7058259EC508Q66059146-A5127553-E3F8-4305-91F5-E2762C2BE544Q66060668-38C385C1-328D-4C43-9427-90C1BC8B7854Q66062105-99D9FF4D-DF04-4B3F-84DE-28E98494C7F8Q66065666-1008E333-9A6A-44AD-B5B1-771D4FB31724Q66076075-0FDC191B-8AE7-4272-B303-7308CBC22481Q66083373-0E6DCAF0-A4AB-4A99-969E-7FDD34B77C29Q66392955-E6A7DF16-045A-4FA2-BDF6-A3AE1D68B2F2Q66406800-BA0024F2-CB54-4F12-B4E1-541AF067E7FAQ66410713-201FED22-D0E7-4C3A-AAF2-34A988FC1CA2Q67124334-06E1871C-4C16-412C-9114-DDBF5CDACD79Q86298463-719246E8-0964-4484-ADBA-E95FD41D2BC8Q92193758-835572D9-43C6-4519-8C68-3DEF8B60D9BA
P1050
description
Krankheit
@de
condition in which polyneuropathy and polyradiculopathy occur together
@en
name
poliradiculoneuropatía
@es
polyradiculoneuropathy
@en
polyradiculonévrite
@fr
polyradikulonevropati
@nb
polyradikulonevropati
@nn
পলিরাডিকুলোপ্যাথি
@bn
type
label
poliradiculoneuropatía
@es
polyradiculoneuropathy
@en
polyradiculonévrite
@fr
polyradikulonevropati
@nb
polyradikulonevropati
@nn
পলিরাডিকুলোপ্যাথি
@bn
altLabel
Polyradiculoneuropathy (disorder)
@en
Polyradiculoneuropathy
@en
Polyradiculonevrite
@fr
prefLabel
poliradiculoneuropatía
@es
polyradiculoneuropathy
@en
polyradiculonévrite
@fr
polyradikulonevropati
@nb
polyradikulonevropati
@nn
পলিরাডিকুলোপ্যাথি
@bn
P672
P486
P6366
P1995
P2892
P31
P3827
polyradiculoneuropathy
P486
P5270
MONDO:0006915
P6366
2777052087
P672
C10.114.750
C10.314.750
C10.668.829.800.750
C20.111.258.750